US Patent

US9050307 — Method for the preparation of a levothyroxine solution

Formulation · Assigned to EMP Pharma GmbH · Expires 2031-08-06 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method for preparing an oral levothyroxine composition with improved storage stability.

USPTO Abstract

Levothyroxine, also known as L-thyroxine, synthetic T4, or 3,5,3′,5′-tetraiodo-L-thyronine, CAS number 51-48-9, is a synthetic form of thyroxine, used as a hormone substitute for patients with thyroid conditions. The invention relates to a method for the preparation of an oral levothyroxine composition. The method according to the invention results in liquid levothyroxine formulations that have improved storage stability compared to known liquid levothyroxine formulations.

Drugs covered by this patent

Patent Metadata

Patent number
US9050307
Jurisdiction
US
Classification
Formulation
Expires
2031-08-06
Drug substance claim
No
Drug product claim
Yes
Assignee
EMP Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.